单细胞RNA测序揭示基质演化为LRRC15+肌成纤维细胞决定免疫治疗反应
研究通过单细胞转录组学描绘胰腺导管腺癌(PDAC)动物模型进展中的成纤维细胞图谱,鉴定出由TGFβ编程、表达LRRC15的癌相关成纤维细胞(CAF)亚群。在22例PDAC患者超过8万个单细胞及70例患者IHC样本中验证LRRC15+ CAF存在。涉及六种癌症类型、超过600例患者的免疫治疗临床试验数据显示,LRRC15+ CAF特征升高与抗PD-L1治疗反应差相关。
要点
- LRRC15+ CAF由TGFβ编程,环绕肿瘤岛,正常胰腺组织缺失。
- LRRC15+ CAF特征升高与抗PD-L1治疗反应差相关。
- 靶向LRRC15+ CAF或可增强免疫检查点阻断疗效。
核心结论
- TGFβ驱动的LRRC15+ CAF谱系与多种实体瘤免疫治疗不良结局相关,是联合治疗潜在靶点。
研究设计与样本
- 研究使用单细胞转录组学描绘PDAC动物模型进展中的成纤维细胞 landscape,并在22例PDAC患者超过8万个单细胞及70例患者IHC样本中验证。
- 免疫治疗临床试验数据涵盖六种癌症类型、超过600例患者,分析LRRC15+ CAF特征与抗PD-L1治疗反应的关系。
主要发现
- 鉴定出由TGFβ编程、表达LRRC15的CAF亚群,环绕肿瘤岛,正常胰腺组织缺失。
- 在22例PDAC患者超过8万个单细胞及70例患者IHC样本中确认LRRC15+ CAF存在。
- 六种癌症类型、超过600例患者的免疫治疗临床试验数据显示,LRRC15+ CAF特征升高与抗PD-L1治疗反应差相关。
临床怎么用
- LRRC15+ CAF特征或可作为抗PD-L1治疗反应差的生物标志物。
- 靶向LRRC15+ CAF的联合策略可能提升免疫检查点阻断疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
With only a fraction of patients responding to cancer immunotherapy, a better understanding of the entire tumor microenvironment is needed. Using single-cell transcriptomics, we chart the fibroblastic landscape during pancreatic ductal adenocarcinoma (PDAC) progression in animal models. We identify a population of carcinoma-associated fibroblasts (CAF) that are programmed by TGFβ and express the leucine-rich repeat containing 15 (LRRC15) protein. These LRRC15+ CAFs surround tumor islets and are absent from normal pancreatic tissue. The presence of LRRC15+ CAFs in human patients was confirmed in >80,000 single cells from 22 patients with PDAC as well as by using IHC on samples from 70 patients. Furthermore, immunotherapy clinical trials comprising more than 600 patients across six cancer types revealed elevated levels of the LRRC15+ CAF signature correlated with poor response to anti-PD-L1 therapy. This work has important implications for targeting nonimmune elements of the tumor microenvironment to boost responses of patients with cancer to immune checkpoint blockade therapy. SIGNIFICANCE: This study describes the single-cell landscape of CAFs in pancreatic cancer during in vivo tumor evolution. A TGFβ-driven, LRRC15+ CAF lineage is associated with poor outcome in immunotherapy trial data comprising multiple solid-tumor entities and represents a target for combinatorial therapy.This article is highlighted in the In This Issue feature, p. 161.
引用
- Dominguez CX, Müller S, Keerthivasan S, et al. Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15+ Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy. Cancer Discov. 2019. PMID: 31699795. doi:10.1158/2159-8290.CD-19-0644
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。